Clinical Trials Logo

Beta-Thalassemia clinical trials

View clinical trials related to Beta-Thalassemia.

Filter by:

NCT ID: NCT06041620 Recruiting - Thalassemia Major Clinical Trials

Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells

Start date: August 31, 2023
Phase: N/A
Study type: Interventional

This is a single-arm, open, single-injection exploratory clinical study with two transfusion-dependent β thalassemia (β-TDT) participants planned to enroll.

NCT ID: NCT05991336 Recruiting - Gene Therapy Clinical Trials

Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy

Start date: June 5, 2023
Phase:
Study type: Observational

The investigate will conduct a cohort study to compare the growth and development, metabolism, lifestyle behavior, and health-related quality of life among three groups: children with transfusion-dependent β-thalassemia (TDT) who have received gene therapy, TDT children with lifelong supportive therapy and healthy children.

NCT ID: NCT05891249 Recruiting - Anemia Clinical Trials

A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India

Start date: June 5, 2023
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of luspatercept in participants who require regular blood cell transfusions due to b-thalassemia and myelodysplastic syndromes in India

NCT ID: NCT05864170 Recruiting - ß-thalassemia Clinical Trials

the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia

Start date: May 27, 2022
Phase: Early Phase 1
Study type: Interventional

This is an open label study to evaluate the safety and efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients

NCT ID: NCT05860595 Recruiting - Clinical trials for Transfusion-dependent Beta-Thalassemia

Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.

Start date: May 23, 2023
Phase: N/A
Study type: Interventional

This is a non-randomized, open-label, single-dose study. The aim of this study is to evaluate the safety and efficacy of the treatment with lentiviral vector encoding βA-T87Q-globin gene transduced autologous hematopoietic stem cells in subjects with β-thalassemia major.

NCT ID: NCT05799118 Recruiting - Sickle Cell Disease Clinical Trials

Study of the Role of Genetic Modifiers in Hemoglobinopathies

INHERENT
Start date: October 1, 2022
Phase:
Study type: Observational

This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).

NCT ID: NCT05776173 Recruiting - ß-thalassemia Major Clinical Trials

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia

Start date: August 10, 2023
Phase: N/A
Study type: Interventional

This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector encoding the human βA-T87Q-globin gene in patients with transfusion-dependent (TDT) β-thalassemia.

NCT ID: NCT05773729 Recruiting - ß-thalassemia Clinical Trials

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia

Start date: September 15, 2023
Phase: N/A
Study type: Interventional

This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector encoding the human βA-T87Q-globin gene in patients with transfusion-dependent (TDT) β-thalassemia.

NCT ID: NCT05762510 Recruiting - Clinical trials for Transfusion Dependent Beta-Thalassemia

A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]

Start date: February 22, 2023
Phase: Early Phase 1
Study type: Interventional

This is a single-arm, open label, single-dose study in subjects with transfusion dependent β-thalassaemia. The study will evaluate the safety and efficacy of autologous CD34+ Human Hematopoietic Stem Cells that was transduced with LentiRed Lentivrial vector.

NCT ID: NCT05745532 Recruiting - ß-thalassemia Clinical Trials

Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

Start date: December 1, 2020
Phase: Early Phase 1
Study type: Interventional

This is an open label study to evaluate the safety and efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients